Details

Autor(en) / Beteiligte

• Ding, Yan
• Hou, Yapeng
• Liu, Yanhong
• Xie, Xiaoyong
• Cui, Yong
• Nie, Hongguang

Titel

Prospects for miR-21 as a Target in the Treatment of Lung Diseases

Ist Teil von

• Current pharmaceutical design, 2021, Vol.27 (3), p.415-422

Ort / Verlag

United Arab Emirates

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• MicroRNA (miRNA/miR) is a class of small evolutionarily conserved non-coding RNA, which can inhibit the target gene expression at the post-transcriptional level and serve as significant roles in cell differentiation, proliferation, migration and apoptosis. Of note, the aberrant miR-21 has been involved in the generation and development of multiple lung diseases, and identified as a candidate of biomarker, therapeutic target, or indicator of prognosis. MiR-21 relieves acute lung injury via depressing the PTEN/Foxo1-TLR4/NF-κB signaling cascade, whereas promotes lung cancer cell growth, metastasis, and chemo/radio-resistance by decreasing the expression of PTEN and PDCD4 and promoting the PI3K/AKT transduction. The purpose of this review is to elucidate the potential mechanisms of miR-21 associated lung diseases, with an emphasis on its dual regulating effects, which will trigger novel paradigms in molecular therapy.